Replies to post #402250 on Anavex Life Sciences Corp (AVXL)

[bas2020]

I'll gladly take your shares...

I personally am slowly reducing my position

[georgejjl]

Correction:

The Phase 3 Alzheimer's trial using blarcamesine ia a success that met or exceeded its primary and secondary endpoints with both statistical and clinical significance.

THAT IS A FACT.

ANAVEX®2-73 (BLARCAMESINE) PHASE 2B/3 STUDY MET PRIMARY AND KEY SECONDARY ENDPOINTS,
SHOWING STATISTICALLY SIGNIFICANT REDUCTION OF CLINICAL DECLINE IN GLOBAL CLINICAL STUDY OF PATIENTS WITH EARLY ALZHEIMER’S DISEASE

Robust, Statistically Significant and Clinically Meaningful Absolute Improvement in Cognitive Function as Measured by ADAS-Cog and ADCS-ADL
Key Secondary Endpoint CDR-SB Also Met, Demonstrating Statistically Significant Results
Plan to Meet with Regulatory Authorities to Determine Next Steps

Good luck and GOD bless,

[$Money Bags$]

I think all of it in rides on Rhett's. If that gets approved, it'll likely start getting quite a bit off label use which will generate more than Rhett's usage imo. We had great success for an ailment my wife had with off label drug use and it was worth all the hassel and every penny. When someone's back is against the wall, they will try just about anything in their means.